{
  "input": {
    "mode": "build_counterchain",
    "query": {
      "entity": "Gastrointestinal epithelial barrier disorders",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_mesalamine",
          "name": "Mesalamine"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_azathioprine",
          "name": "Azathioprine"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_budesonide",
          "name": "Budesonide"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_certolizumab_pegol",
          "name": "Certolizumab pegol"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_golimumab",
          "name": "Golimumab"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_vedolizumab",
          "name": "Vedolizumab"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_linaclotide",
          "name": "Linaclotide"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_rifaximin",
          "name": "Rifaximin"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_eluxadoline",
          "name": "Eluxadoline"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "tegraph_snapshot": {
      "nodes": [],
      "edges": [],
      "round_index": 4
    },
    "constraints": {
      "max_new_nodes": 50,
      "max_new_edges": 64,
      "batched": true
    },
    "ablation_config": {
      "enable_debate": true,
      "enable_skeptic": true,
      "enable_pi_interrupts": true,
      "enable_textual_feedback": true,
      "enable_heuristic_transfer": true,
      "enable_seed_regen": true,
      "weights": {
        "path_disjointness": 1.0
      },
      "mode": "graph"
    }
  },
  "output": {
    "graph_updates": {
      "add_nodes": [
        {
          "id": "n_ot_mesalamine",
          "type": "Target",
          "label": "Mesalamine Off-Target Effects",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_mesalamine",
          "type": "Pathway",
          "label": "Mesalamine Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_mesalamine",
          "type": "Phenotype",
          "label": "Adverse Effects of Mesalamine",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "Infliximab Off-Target Effects",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_infliximab",
          "type": "Pathway",
          "label": "Infliximab Risk Pathway",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_infliximab",
          "type": "Phenotype",
          "label": "Adverse Effects of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "add_edges": [
        {
          "source": "drug_mesalamine",
          "target": "n_ot_mesalamine",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Skeptic",
          "rationale": "Potential off-target effects may contribute to adverse outcomes."
        },
        {
          "source": "n_ot_mesalamine",
          "target": "n_rp_mesalamine",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "Risk pathway involvement suggests adverse consequences."
        },
        {
          "source": "n_rp_mesalamine",
          "target": "n_adv_mesalamine",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "May lead to significant adverse phenotypes."
        },
        {
          "source": "n_adv_mesalamine",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "If risks materialize, they could negate perceived benefits."
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.65,
          "agent": "Skeptic",
          "rationale": "Potential off-target effects may contribute to adverse outcomes."
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp_infliximab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "Risk pathway involvement suggests adverse consequences."
        },
        {
          "source": "n_rp_infliximab",
          "target": "n_adv_infliximab",
          "relation": "causes",
          "weight": 0.75,
          "agent": "Skeptic",
          "rationale": "May lead to significant adverse phenotypes."
        },
        {
          "source": "n_adv_infliximab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "If risks materialize, they could negate perceived benefits."
        }
      ],
      "merge": [],
      "set_weights": [],
      "conflict_hotspots": [
        {
          "topic": "Drug Efficacy vs Off-Target Effects",
          "pro_nodes": [
            "drug_mesalamine",
            "drug_infliximab"
          ],
          "con_nodes": [
            "n_rp_mesalamine",
            "n_rp_infliximab"
          ],
          "note": "Efficacy claims potentially conflict with off-target risks"
        }
      ]
    },
    "counterclaims": [
      {
        "id": "K1",
        "text": "存在支持不良反应链的文献，挑战积极干预的有效性",
        "confidence": "high"
      },
      {
        "id": "K2",
        "text": "靶向组织暴露不足，可能影响疗效",
        "confidence": "medium"
      }
    ],
    "assumptions_challenged": [
      "靶药物作用机制是否全面考量",
      "是否评估了长期安全性"
    ],
    "falsification_tests": [
      "是否有临床数据支持长期效果与安全性",
      "是否能验证疗效与副作用之间的平衡"
    ],
    "next_focus_for_pi": [
      "要求 Proponent 使用证据阐释副作用机制",
      "对 konflikt hotspot 进行深入分析"
    ]
  }
}